Literature DB >> 22447963

Enhanced pulmonary arteriopathy in simian immunodeficiency virus-infected macaques exposed to morphine.

Leslie Spikes1, Pranjali Dalvi, Ossama Tawfik, Haihua Gu, Norbert F Voelkel, Paul Cheney, Amy O'Brien-Ladner, Navneet K Dhillon.   

Abstract

RATIONALE: HIV-associated pulmonary arterial hypertension (PAH) is likely a more prevalent noninfectious complication of AIDS than previously recognized. Furthermore, the majority of HIV-PAH cases occur in individuals with a history of intravenous drug use. In this study we used a simian immunodeficiency (SIV) macaque model and a primary cell-culture system to investigate the association between drug abuse and HIV infection in HIV-PAH development.
METHODS: The archival lung tissues from macaques previously used to study the effect of morphine on SIV infection-associated neuropathogenesis were analyzed for pulmonary vascular changes. The direct effect of HIV proteins and illicit drugs was investigated on oxidative stress, survival, and proliferation of human pulmonary microvascular endothelial cells.
MEASUREMENTS AND MAIN RESULTS: SIVmacR71/17E-infected rhesus macaques treated with morphine (VM group) demonstrated significant pulmonary vascular remodeling, including the presence of early and advanced complex (plexiform) lesions, when compared with either the SIV-infected (V group) or morphine-treated uninfected (M group) macaques. However, both the V (two of five) and VM (two of six) groups included some animals with Pneumocystis jirovecii pneumonia. The endothelial cells lining the vessels with medial hypertrophy or initial-stage intimal lesions in lung sections from VM macaques demonstrated an increase in positivity for both terminal dUTP nick-end labeling and Ki67. Oxidative stress-mediated enhanced apoptosis followed by enhanced proliferation of endothelial cells was observed on simultaneous treatment with viral proteins and drugs of abuse compared with either treatment alone.
CONCLUSIONS: Our findings suggest that SIV/HIV protein(s) and morphine interact to cause the proliferation of apoptosis-resistant endothelial cells leading to angio-obliteration.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22447963      PMCID: PMC3373069          DOI: 10.1164/rccm.201110-1909OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  49 in total

1.  Dual effects of morphine on permeability and apoptosis of vascular endothelial cells: morphine potentiates lipopolysaccharide-induced permeability and apoptosis of vascular endothelial cells.

Authors:  Hsien-Ching Liu; Jenine K Anday; Steven D House; Sulie L Chang
Journal:  J Neuroimmunol       Date:  2004-01       Impact factor: 3.478

2.  Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR.

Authors:  Renata Colavitti; Giovanni Pani; Barbara Bedogni; Rosanna Anzevino; Silvia Borrello; Johannes Waltenberger; Tommaso Galeotti
Journal:  J Biol Chem       Date:  2001-11-21       Impact factor: 5.157

3.  Cardiopulmonary function in individuals with HIV infection in the antiretroviral therapy era.

Authors:  Alison Morris; Matthew R Gingo; M Patricia George; Lorrie Lucht; Cathy Kessinger; Vikas Singh; Maria Hillenbrand; Michelle Busch; Deborah McMahon; Karen A Norris; Hunter C Champion; Mark T Gladwin; Yingze Zhang; Chad Steele; Frank C Sciurba
Journal:  AIDS       Date:  2012-03-27       Impact factor: 4.177

Review 4.  The effects of HIV infection on endothelial function.

Authors:  D Chi; J Henry; J Kelley; R Thorpe; J K Smith; G Krishnaswamy
Journal:  Endothelium       Date:  2000

Review 5.  HIV-Related pulmonary hypertension: analytic review of 131 cases.

Authors:  N J Mehta; I A Khan; R N Mehta; D A Sepkowitz
Journal:  Chest       Date:  2000-10       Impact factor: 9.410

6.  Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension.

Authors:  Hilario Nunes; Marc Humbert; Olivier Sitbon; Jane H Morse; Zemin Deng; James A Knowles; Catherine Le Gall; Florence Parent; Gilles Garcia; Philippe Hervé; Robyn J Barst; Gérald Simonneau
Journal:  Am J Respir Crit Care Med       Date:  2003-02-25       Impact factor: 21.405

7.  HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells.

Authors:  Ibolya E András; Hong Pu; Mária A Deli; Avindra Nath; Bernhard Hennig; Michal Toborek
Journal:  J Neurosci Res       Date:  2003-10-15       Impact factor: 4.164

8.  Primary pulmonary hypertension in HIV infection.

Authors:  R Speich; R Jenni; M Opravil; M Pfab; E W Russi
Journal:  Chest       Date:  1991-11       Impact factor: 9.410

9.  Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells.

Authors:  Jan K Damås; Kari Otterdal; Arne Yndestad; Halfdan Aass; Nils O Solum; Stig S Frøland; Svein Simonsen; Pål Aukrust; Arne K Andreassen
Journal:  Circulation       Date:  2004-08-09       Impact factor: 29.690

10.  Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth.

Authors:  Kalpna Gupta; Smita Kshirsagar; Liming Chang; Robert Schwartz; Ping-Y Law; Doug Yee; Robert P Hebbel
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

View more
  30 in total

1.  Injection drug use as a "second hit" in the pathogenesis of HIV-associated pulmonary hypertension.

Authors:  M Patricia George; Hunter C Champion; Mark T Gladwin; Karen A Norris; Alison Morris
Journal:  Am J Respir Crit Care Med       Date:  2012-06-01       Impact factor: 21.405

Review 2.  Drug abuse and HIV-related pulmonary hypertension: double hit injury.

Authors:  Zachery J Harter; Stuti Agarwal; Pranjali Dalvi; Norbert F Voelkel; Navneet K Dhillon
Journal:  AIDS       Date:  2018-11-28       Impact factor: 4.177

3.  Ligand-Independent Activation of Platelet-Derived Growth Factor Receptor β during Human Immunodeficiency Virus-Transactivator of Transcription and Cocaine-Mediated Smooth Muscle Hyperplasia.

Authors:  Pranjali N Dalvi; Vijayalaxmi G Gupta; Brooke R Griffin; Amy O'Brien-Ladner; Navneet K Dhillon
Journal:  Am J Respir Cell Mol Biol       Date:  2015-09       Impact factor: 6.914

Review 4.  Mechanisms Underlying HIV-Associated Noninfectious Lung Disease.

Authors:  Rachel M Presti; Sonia C Flores; Brent E Palmer; Jeffrey J Atkinson; Catherine R Lesko; Bryan Lau; Andrew P Fontenot; Jesse Roman; John F McDyer; Homer L Twigg
Journal:  Chest       Date:  2017-04-17       Impact factor: 9.410

Review 5.  The complexity of HIV persistence and pathogenesis in the lung under antiretroviral therapy: challenges beyond AIDS.

Authors:  Sharilyn Almodovar
Journal:  Viral Immunol       Date:  2014-05-05       Impact factor: 2.257

6.  Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists.

Authors:  Mark E Orcholski; Ke Yuan; Charlotte Rajasingh; Halley Tsai; Elya A Shamskhou; Navneet K Dhillon; Norbert F Voelkel; Roham T Zamanian; Vinicio A de Jesus Perez
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-02-08       Impact factor: 5.464

7.  Lung Vascular Remodeling, Cardiac Hypertrophy, and Inflammatory Cytokines in SHIVnef-Infected Macaques.

Authors:  Sharilyn Almodovar; Jessica Swanson; Luis D Giavedoni; Sreetharan Kanthaswamy; Carlin S Long; Norbert F Voelkel; Michael G Edwards; Joy M Folkvord; Elizabeth Connick; Susan V Westmoreland; Paul A Luciw; Sonia C Flores
Journal:  Viral Immunol       Date:  2017-12-19       Impact factor: 2.257

Review 8.  Pathogenesis of HIV and the lung.

Authors:  Matthew R Gingo; Alison Morris
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

Review 9.  Human immunodeficiency virus-associated pulmonary arterial hypertension.

Authors:  Christopher F Barnett; Priscilla Y Hsue
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

Review 10.  Non-infectious Pulmonary Diseases and HIV.

Authors:  M Triplette; K Crothers; E F Attia
Journal:  Curr HIV/AIDS Rep       Date:  2016-06       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.